Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $23.14 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.